Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Amgen's Future Is Brighter Than You Might Think

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

When you think about a cutting-edge, one-foot-in-the-future biotech company, no one would blame you for skipping over Amgen (NASDAQ: AMGN  ) . You don't have to look very hard to find a headline labeling it as an aging pharmaceutical company grappling with a fading market presence and lack of ingenuity in the pipeline. Some may even argue that Amgen's future isn't as bright as its biotech competitors.

I couldn't disagree more. In fact, earlier this month CEO Robert A. Bradway outlined his long-term strategy for growth that focuses on three key areas:

  1. Selective research and development with "biology first" policy.
  2. Transformation of the commercial model.
  3. New manufacturing technologies.

What does it all mean? Let's take a closer look.

Pipeline outlook
Amgen's pipeline stacks up pretty favorably with its peers, especially in late-stage development:


Ongoing Phase 3 Trials

Biologics in Phase 3 Trials




Celgene (NASDAQ: CELG  )



Biogen Idec (NASDAQ: BIIB  )



Gilead (NASDAQ: GILD  )



Source: Company websites. 

As of today, the company expects results from two pivotal phase 3 trials this year, five more in 2014, and one in 2016. That doesn't beat Celgene, which is expecting data from more than 10 phase 3 trials this year, but it does dismiss any claims that Amgen has lost its ability to innovate.

I recently pointed out why Celgene was my favorite big biotech for 2013. I'm not backing down from that opinion -- I just think several companies finished a close second. Other than Amgen, Gilead and Biogen have promising drugs on the market and in their pipelines as well. Gilead, which has several of the market's brightest drugs, has five biologics in phase 2 trials not included in the table. And although Biogen began 2013 with a failed phase 3 trial, its focus on pure biologics is unrivaled.

Amgen's size and market presence deserve an analysis of its own. Consider that Neulasta/Neupogen, the company's top drug, nearly brought in more revenue last year than the totals enjoyed by Celgene and Gilead.   

Decoding "biology first"
The pipeline is being driven by a "biology first" policy, which aligns development selectivity with human genetics. A recently acquired treasure trove of human genetic data from deCODE Genetics could pay tremendous long-term dividends. What's the importance?

Over the past 17 years, deCODE Genetics created dozens of innovative analysis techniques to mine genetic data from large populations. The company used Iceland's mostly homogenous population to sweep through the human genome with unparalleled precision. Discrepancies in gene expression were easier to notice in the population and less likely to be caused from racial genetic differences, thus making genes linked to various diseases stand out with scientific significance.

The result? deCode found genetic risk factors for dozens of diseases that have spurred a modern-day gold rush into population genetics. One such highly targeted therapy developed with genetic analysis was Herceptin from Roche (NASDAQOTH: RHHBY  ) , which generated $6.4 billion in 2012 sales. Essentially, deCODE took the first step in developing one of the Holy Grails of health care: individualized medicine.

Now all of those innovative analysis techniques belong to Amgen, which hopes to use it to take some of the guesswork out of biologics development. Don't get me wrong -- all companies developing biologics today understand the importance of genetics. Amgen has just made one of the more aggressive moves to ensure it remains a top focus.

Biologics manufacturing
Gaining approval for a biologic involves a bit more paperwork than a small molecule. Even biosimilars -- the generic versions of a biologic -- take longer to get a regulatory nod than small-molecule generics do. What's the holdup? Biologics are approved on data submitted from trials and manufacturing facilities.

Biomanufacturing facilities can cost a pretty penny, too. Genzyme recently built a facility for $175 million, or $22,000 per liter of bioreactor. Investments in that neighborhood keep smaller companies from crowding the industry, prices high, and generic competition low. Nonetheless, permanent investments in biomanufacturing are a great way to gauge the growth of any pipeline.  

Amgen recently announced plans to build the world's newest biomanufacturing facility in Singapore that will cost $200 million, likely pegging it near $20,000 per liter of bioreactor as well. The facility will be used exclusively for monoclonal antibodies, which are quickly outgrowing the company's current production capacity.

Amgen's best-selling antibodies -- Vectibix, Prolia, and XGEVA -- brought in $1.58 billion in sales last year and are expected to breach $3 billion in the next few years. The facility will also come in handy for its newly planned portfolio of six biosimilars, which the company believes represent a multibillion-dollar opportunity.  

Foolish bottom line
Investors looking to buy into the future of biotechnology would be making a grave mistake by glossing over Amgen. The company may be considered part of the "old guard," but it hasn't lost its ability to innovate or its focus on the future of medicine.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 19, 2013, at 9:55 AM, prginww wrote:

    If there is no innovation, then key areas #2 and 3 don't matter. So it comes down to the pipeline. They have been expecting results from many pivotal phase 3 drugs for years now. Guess what that has yielded?

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2260467, ~/Articles/ArticleHandler.aspx, 9/29/2016 6:36:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
AMGN $165.45 Down -4.26 -2.51%
Amgen CAPS Rating: ****
BIIB $305.78 Down -4.77 -1.54%
Biogen CAPS Rating: *****
CELG $102.77 Down -3.06 -2.89%
Celgene CAPS Rating: *****
GILD $77.86 Down -1.11 -1.41%
Gilead Sciences CAPS Rating: *****
RHHBY $31.01 Down -0.56 -1.77%
Roche Holding Ltd.… CAPS Rating: *****